Last reviewed · How we verify
NCT05312983: AUDIOGENAGE
Development of a Battery of Audiological Tests for the Precision Diagnosis of Age-related Hearing Loss
NA trial testing Audiological and vestibular tests in Presbyacusis in 700 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Institut Pasteur |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 700 |
| Start date | 28 July 2022 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2030 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Audiological and vestibular tests
- Blood sampling — full drug profile →
- neurocognitive self-questionnaire
Conditions studied
- Presbyacusis — all drugs for Presbyacusis →
Sponsor
Institut Pasteur — full company profile →
Who can join
18 and older, any sex, with Presbyacusis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Age-related hearing loss, or presbycusis, is caused by many genetic and environmental factors. Its prevalence poses a public health challenge of early identification and effective hearing aid treatment. However, the lack of screening and of a validated audiological test battery to diagnose an individual's needs and to guide hearing aid adjustments is a major obstacle. Furthermore, monogenic forms of hearing loss affect only one functional module of hearing. The audiological test(s) dependent on the function of this module are affected, in a progressive manner, but not the others. A previous study showed that in early onset presbycusis patients, a quarter of the subjects tested were affected by monogenic presbycusis. The collection of audiological and vestibular tests, carried out on proven monogenic presbycusis patients and compared to that of normal hearing patients, would constitute a battery of tests allowing a precision diagnosis, then developed to all forms of presbycusis in order to study if the identification of abnormal functional modules can usefully guide the diagnosis and the early fitting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05312983
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut Pasteur trials
Trials by the same sponsor.
- NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
- NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
- NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
- NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
- NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05312983 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05312983.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing